[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"}]